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Background: Chronic obstructive pulmonary disease (COPD) patients are thought to have
limited bronchodilator response, determined by changes in forced expiratory volume in
1 s (FEV1). In this study, we assessed bronchodilator response in patients with COPD using
not only FEV1 but also changes in lung volume expressed as forced vital capacity (FVC)
and inspiratory capacity (IC). We also evaluated the speed of onset of bronchodilation.
Methods: Data were from 2 randomized, double-blind, placebo-controlled studies (6-months
[NCT00206154]; 12-months [NCT00206167]) in patients with moderate to very severe COPD.
Treatments: twice daily budesonide/formoterol pressurized metered-dose inhaler (pMDI)
320/9 mg, budesonide/formoterol pMDI 160/9 mg, formoterol dry powder inhaler (DPI) 9 mg,
placebo.
Results: The percentage of patients with FEV1 improvement (12% and 200 mL; American
Thoracic Society [ATS] criterion) was 34e39% post-albuterol (screening). On day of randomiza-
tion (DOR), a larger proportion receiving formoterol-containing treatment exhibited revers-
ibility within 60 min: FEV1 (57e59%). Similar results were seen for IC (50e61%) and
FVC (57e67%) using the same improvement criteria. The time to 15% FEV1 improvement on
DOR was 5.0, 4.8, and 7.3 min for budesonide/formoterol 320/9, budesonide/formoterol
160/9, and formoterol, respectively. Time to 15% FEV1 improvement was better maintained
with budesonide/formoterol than formoterol at treatment end (6 and 12 months).c Society; BUD, budesonide; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler;
FM, formoterol; FVC, forced vital capacity; IC, inspiratory capacity; ICS, inhaled corticosteroid; LABA,
O, placebo; pMDI, pressurized metered-dose inhaler; TLC, total lung capacity; TORCH, Towards
Understanding Potential Long-Term Impacts on Function with Tiotropium trial.
7 307 0310; fax: þ1 617 582 6011.
g (B.R. Celli).
1 Published by Elsevier Ltd.
Budesonide/formoterol reversibility and onset in COPD 1177Conclusions: Most patients with moderate to very severe COPD exhibit ATS-defined bronchodi-
lator reversibility based on flow and lung volume measures after budesonide/formoterol pMDI
or formoterol treatment. Budesonide/formoterol pMDI also has a rapid (within 5 min) onset of
bronchodilation that is maintained over time compared with formoterol alone.
ª 2011 Published by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disease (COPD) is a treat-
able and preventable disease with airflow obstruction that
is not fully reversible.1,2 Characterization of bronchodilator
responsiveness is complex in patients with COPD since
several factors may influence the results of reversibility
testing, including daily variation in initial airway caliber
and forced expiratory volume in 1 second (FEV1).
1,3 In
addition, poor short-term bronchodilator response does not
preclude a long-term response to maintenance bronchodi-
lator therapy.4,5 Thus, current COPD guidelines recommend
against using reversibility testing to predict a patient’s
clinical response to long-term bronchodilator therapy.1,3
Patients with COPD are thought to have a limited response
tobronchodilators. However, Tashkinet al. reported that over
half of the patients withmoderate to very severe COPD in the
Understanding Potential Long-Term Impacts on Function with
Tiotropium (UPLIFT) trial demonstrated reversibility to 2
short-acting bronchodilators combined (ipratropium bromide
80 mg 4 inhalations followed by albuterol 400 mg 4 inha-
lations) based on a12% and200 mL improvement in FEV1.6
In that study, a smaller proportion of patients with more
severe obstruction (Global initiative for chronic Obstructive
Lung Disease [GOLD] stages III and IV) manifested a significant
FEV1 response compared with patients with milder obstruc-
tion (GOLD stage II).6 Although not sufficiently emphasized in
the article, a review of the data from that study showed that
a large proportion of the GOLD stage IIIeIV patients had
a response in terms of lung volume as measure by forced vital
capacity (FVC).6 In addition, inspiratory capacity (IC) was not
reported in that study.6 Clinical benefits of maintenance
therapy with a long-acting b2-adrenergic agonist (LABA)
administered alone or in combination with an inhaled corti-
costeroid (ICS) also have been demonstrated in patients with
COPD across COPD severity categories.7e11
Treatment with the combination of the ICS budesonide
and the LABA formoterol administered in one dry powder
inhaler (DPI; Symbicort Turbuhaler, AstraZeneca, Lund,
Sweden) has been shown to improve pulmonary function,
health-related quality of life, and symptoms in patients with
COPD and to reduce the rate of exacerbations compared
with placebo.8,10 Two small studies (nZ 20 randomized12
and nZ 90 randomized13) showed that patients with COPD
treated with budesonide/formoterol experienced a greater
bronchodilator response compared with formoterol alone12
and a faster onset of effect compared with formoterol
alone12 or fluticasone propionate/salmeterol.13
We hypothesized that compared with albuterol or
formoterol, the combination of budesonide/formoterol
would provide a larger bronchodilator response, measured
not only by FEV1 but also in terms of lung volumes. In addi-
tion, we tested whether the speed of bronchodilatorresponse is faster for the combination of budesonide/for-
moterol compared with either monocomponent. To test
these hypotheses, we used pooled data from 2 active- and
placebo-controlled phase III clinical studies (6months and 12
months, respectively) of more than 3500 patients with
moderate to very severe COPD.14,15 From these 2 studies, we
evaluated themagnitude and onset of bronchodilation in the
subset (nZ 1109) of patients for whom sequential lung
function studies were performed.
Methods
Patients
Details of the studies have been reported previously.14,15 In
brief, the populations consisted of patients 40 years of
age with moderate to very severe COPD, representative of
those patients with COPD likely to be treated with an
ICS/LABA combination.
Study design and treatments
Both studies were randomized, double-blind, double-
dummy, parallel-group, multicenter trials (NCT00206167 and
NCT00206154). Clinic visits occurred at screening, randomi-
zation, and months 1, 2, 4, and 6 in the 6-month study and at
the same time points and months 9 and 12 in the 12-month
study. Patients previously receiving ICS or ICS/LABA therapy
before study enrollment received ICS monotherapy, and
patients previously receiving anticholinergic therapy re-
ceived ipratropium bromide at a stable dose during a 2-week
run-in period. ICS therapy was discontinued at randomiza-
tion; ipratropium therapy was allowed to continue during
the randomized treatment period. Albuterol rescue medi-
cation was permitted throughout the study. After the run-in
period, patients who met the eligibility criteria were
randomized in each trial to one of the treatments shown in
Fig. 1. The study protocols were approved by the human
studies review board committee at each site, and written
informed consent was obtained from patients. The studies
conformed with the Declaration of Helsinki.
Outcome variables
Spirometry was performed according to American Thoracic
Society (ATS) recommendations.16 In the subset of patients
who were willing and able to undergo serial spirometry,
FEV1 was measured predose and 5, 15, 30, 60, 120, 180,
240, 360, 480, 600, and 720 min after study medication on
the day of randomization and at the end of months 2 and
6 in the 6-month study and on the day of randomization and
at the end of months 6 and 12 in the 12-month study. On
Figure 1 Patient disposition in the 6-month and 12-month trials. AE, adverse event; bid, twice daily; BUD, budesonide; DPI, dry
powder inhaler; FM, formoterol; inh, inhalation; PBO, placebo; pMDI, pressurized metered-dose inhaler. a Demographic and
baseline characteristics of the overall population were presented previously14,15; b this analysis comprises patients included in the
serial spirometry analysis set.
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15e30 minutes after albuterol 90 mg 2 inhalations. FEV1
data from the screening and randomization visits were used
in the present analysis.
IC was assessed predose and 1-h postdose at randomi-
zation and months 2 and 6 in the 6-month study14 and at
randomization and months 6 and 12 in the 12-month study15
in patients with serial spirometry data. The larger of 2 full
inspirations after stabilization of the basal end-expiratory
volume was accepted for analysis at each time point.
Forced vital capacity (FVC) was assessed predose and
1-hour postdose for all patients at all clinic visits. IC and
FVC data from the randomization visit were used in the
present analysis.
Patients were instructed to refrain from bronchodilator
use before the screening and study visits for at least 6 h for
albuterol, 8 h for ipratropium, and 48 h for long-acting
bronchodilators.Data analyses
The serial spirometry analysis included all patients who
received 1 dose of study medication and had a baseline
predose FEV1 value and 1 postdose FEV1 value.
Bronchodilator responsiveness
Reversibility to albuterol was assessed as the percentage of
patients achieving an improvement in FEV1 of 12% and
200 mL (ATS criteria17) 15e30 minpostdose on the screening
day. Assessment of reversibility during study treatment was
based on the percentage of patients who achieved
improvements in FEV1 of 12% and 200 mL from the pre-
dose value within 30 min or 60 min after administration of
medication on the day of randomization. Analysis of change
in reversibility to formoterol-containing treatment over
time was based on the percentage of patients who achieved
ATS-defined FEV1 reversibility
17 on the day of randomiza-
tion and at the end of treatment. The volume response was
assessed as the percentage of patients who achieved
improvements in IC and FVC of 12% and 200 mL from the
respective predose values 1 h after administration of study
medication on the day of randomization. Mean changes
from baseline (last predose value before the first dose of
randomized treatment) in 1-h postdose FEV1, 1-h postdose
IC, and 1-h postdose FVC also were calculated on the day of
randomization.
In these analyses, data obtained from all patients have
been restricted to the serial spirometry population for
comparison with data collected only from this subset. FEV1
reversibility at randomization was censored at 30 min after
administration of study medication to obtain a relevant
comparison with data obtained at screening. To obtain
relevant comparisons with IC and FVC data, FEV1 revers-
ibility at randomization visits also was assessed based on
either 1-h postdose measurements or sequential serial
measurements censored at 60 min.
Data were pooled for treatment groups common to both
studies (budesonide/formoterol pMDI 320/9 mg, budeso-
nide/formoterol pMDI 160/9 mg, formoterol 9 mg DPI, and
placebo). These data were compared between treatment
groups for the population as a whole and for each COPD GOLDseverity category based on postbronchodilator FEV1 screening
values (moderate, 50e<80%; severe, 30e<50%; very
severe,<30%).1 These data were presented using descriptive
statistics, with no formal hypothesis testing performed.
Time to onset of bronchodilation
Time to onset of bronchodilation was assessed as the
first time point at which an increase in FEV1 of 15% from
baseline was reached within 60 min after dosing on the day
of randomization. A similar assessment was performed
at the end of treatment (end of 6 and 12 months, respec-
tively). The percentages of patients who achieved
improvements in FEV1 of 15% from the predose value
within 60 min after administration of medication on the day
of randomization and at the end of treatment also were
reported. Time to onset of bronchodilation was described
using a KaplaneMeier plot and compared between treat-
ment groups using a log-rank test. The median time to
onset of bronchodilation, defined as the point at which
50% of patients achieved a 15% improvement in FEV1
within 60 min after dosing on the day of randomization, was
calculated for each treatment group within each study and
pooled across the studies. A similar calculation was
performed at the end of treatment for the individual
studies. For all assessments of time to onset of bronchodi-
lation, the data were censored at 60 min.
Factors associated with achievement of ATS-defined
reversibility17 and time to onset of bronchodilation (based on
ATS criteria17) (data censoredat 60 min for both) on the day of
randomization were investigated. Factors analyzed were
treatment (formoterol-containing vs noneformoterol-
containing), sex, age, smoking status (current vs ex-smoker),
smoking history (number of pack-years), use of rescue medi-
cation (inhalations/day), mean total symptom score (0e4) on
the Breathlessness, Cough, and Sputum Scale, medications
used during the run-in period (ICS, oxygen, or xanthine), and
history of comorbidities (coronary artery disease, diabetes, or
hypertension). Multivariate logistic regression analysis and
a Cox proportional hazards model were used to assess the
relationship between these factors (independent variables)
and thedependent variables ofATS-defined reversibility17 and
time to onset of bronchodilation (based on ATS criteria17),
respectively.ResultsPatients
Of the randomized patients, a subset of 618 patients of
1704 in the 6-month trial and 491 patients of 1964 in the
12-month trial underwent serial spirometry testing and
were included in the present analysis (Fig. 1). The baseline
characteristics of the population (Table 1) were similar to
those of the overall populations in each study.14,15 At
screening, the percentage of patients with reversibility to
albuterol was greatest in patients with moderate COPD
(Table 1). About one-third fewer patients in the very
severe than in the severe group demonstrated albuterol
reversibility.
Table 1 Patient demographics and baseline clinical characteristics by COPD severity (serial spirometry population).
Variable Moderate
(nZ 236)
Severe
(nZ 598)
Very severe
(nZ 272)
Total
(nZ 1109)a
Sex, n (%)
Female 124 (52.5) 212 (35.5) 86 (31.6) 423 (38.1)
Male 112 (47.5) 386 (64.5) 186 (68.4) 686 (61.9)
Age (years)
Mean (SD) 62.5 (10.0) 64.0 (9.0) 63.6 (8.9) 63.6 (9.2)
Range 40e90 41e88 42e84 40e90
Smoking history, median pack-years 45 42 48 45
Predose FEV1 at screening (visit 1)
Liters, mean (SD) 1.3 (0.3) 1.1 (0.3) 0.7 (0.2) 1.0 (0.4)c
% Predicted, mean (SD) 45.2 (5.2) 35.2 (6.3) 21.9 (4.6) 34.1 (9.8)c
Predose FEV1 at randomization (visit 2)
Liters, mean (SD) 1.4 (0.4) 1.0 (0.3) 0.7 (0.2) 1.0 (0.4)
% Reversibilityb at screening 12%þ change in FEV1 200 mL, n (%) 168 (71.2) 196 (32.8) 38 (14.0) 402 (36.2)
% Reversibilityb at screening 15% FEV1 improvement, n (%) 170 (72.0) 283 (47.3) 126 (46.3) 579 (52.2)
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; SD, standard deviation.
a Includes 3 patients with missing data for whom baseline data by severity were not calculated.
b Reversibility was assessed based on improvements in FEV1 from the prebronchodilator value to the postbronchodilator value
15e30 min after administration of 2 inhalations of albuterol pressurized metered-dose inhaler (total dose 180e200 mg).
c nZ 1108.
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FEV1 and lung volume responsiveness
The percentage of patients who demonstrated ATS-defined
reversibility17within30 minwas51e54%after administration
of formoterol-containing treatments on the day of random-
ization. By comparison, only 34e39% of patients in the
same population had shown reversibility to albuterol. The
percentage of patients who demonstrated reversibility based
on FEV1 within 60 min was 57e59% after administration of
formoterol-containing treatments on the day of randomiza-
tion (Fig. 2, Panel A [all severity categories combined]).
The percentage of patients in all severity categories who
demonstrated ATS-defined reversibility at the end of treat-
ment after being classified as reversible on the day of
randomization was greater in the budesonide/formoterol
pMDI 320/9-mg group (82/108; 75.9%) compared with the
budesonide/formoterol 160/9-mg (57/99; 57.6%) and for-
moterol (56/98; 57.1%) groups. Additionally, the percentage
of patients who remained reversible using ATS-defined
criteria was greater in the formoterol-containing treatment
groups compared with the placebo group (11/22; 50%).
Improvements in IC and FVC of 12% and 200 mL were
achieved by 5061% and 57e67% of patients, respectively,
receiving formoterol-containing treatment (Fig. 2, Panels
B and C).
Responsiveness by disease severity
The proportion of patients with moderate COPD (GOLD stage
II) who exhibited FEV1 reversibility within 30 min after
budesonide/formoterol pMDI treatment (66e69%) on the
day of randomization was greater than that observed within
30 min after formoterol treatment (47%) on the day of
randomization and similar to that observed after albuteroltreatment (71%; Table 1) on the screening day. The
percentage of patients with severe COPD (GOLD stage III)
exhibiting FEV1 reversibility was lower after albuterol at
screening (33%) compared to the percentage showing FEV1
reversibility within 30 min after budesonide/formoterol
pMDI (53e56%) or formoterol (62%) treatment on the day of
randomization. Similar results were observed in the very
severe COPD category (GOLD stage IV), where only 14% of
patients had a response to albuterol on the screening day,
while 3641% and 31% showed FEV1 reversibility to budes-
onide/formoterol pMDI or formoterol, respectively, within
30 min of treatment on the day of randomization.
The percentage of patients demonstrating FEV1 revers-
ibility within 60 min was greater in all formoterol-containing
treatment groups compared with placebo in all COPD
severity categories and in both budesonide/formoterol pMDI
groups compared with formoterol in the moderate and very
severe COPD categories (Fig. 2, Panel A). In all COPD severity
categories, the proportion of patients with reversibility of IC
or FVC was greater in the budesonide/formoterol pMDI and
formoterol treatment groups compared with placebo (Fig. 2,
Panels B and C).
Magnitude of responsiveness
In themoderate COPD group, patients receiving budesonide/
formoterol pMDI had numerically greater mean improve-
ments in FEV1, IC, and FVC compared with those receiving
formoterol alone (Fig 3, Panels AeC). For the whole cohort,
the mean absolute improvements from baseline in postdose
FEV1 were greater in the formoterol-containing treatment
groups (180e230 mL) comparedwith placebo (50 mL) (Fig. 3,
Panel A). Similarly, mean absolute improvements from
baseline in postdose IC and FVC were greater in the for-
moterol-containing treatment groups (250e330 mL and
AB
FEV1
IC
All
All
Figure 2 Percentage of patients demonstrating reversibility by study treatment and COPD severity in both studies (pooled data)
on the day of randomization based on FEV1 (A), IC (B), and FVC (C) improvement threshold of 12% and 200 mL. BUD, budesonide;
DPI, dry powder inhaler; FEV1, forced expiratory volume in 1 s; FM, formoterol; FVC, forced vital capacity; IC, inspiratory capacity;
PBO, placebo; pMDI, pressurized metered-dose inhaler.
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Figure 2 (Continued)
1182 B.R. Celli et al.350e410 mL, respectively) compared with placebo (100 mL
for both variables) (Fig. 3, Panels B and C). Assessment by
COPD severity showed greater mean absolute improvements
from baseline in postdose FEV1 with formoterol-containing
treatment in the moderate (200e340 mL) and severe
(200e210 mL) COPD groups compared with the very severe
(110e170 mL) COPD group (Fig. 3, Panel A). In contrast,
improvements in IC and FVC generally were similar across
all severity groups with formoterol-containing treatment
(Fig. 3, Panels B and C).
Time to onset of bronchodilation
The time to onset of bronchodilation on the day of
randomization and at end of treatment for each study, is
shown in Table 2 and Fig. 4. As shown in Fig. 4, Panel A, on the
day of randomization, the time to achieve a 15% improve-
ment in FEV1 was significantly shorter with both doses of
budesonide/formoterol pMDI compared with budesonide
pMDI and placebo and with formoterol DPI compared with
placebo in the 6-month study (p< 0.001). In the 12-month
study, the time to 15% improvement was significantly shorter
with both doses of budesonide/formoterol pMDI and
formoterol DPI compared with placebo (p< 0.001). When
data from both studies were combined, the median time to
onset of 15% improvement in FEV1 was 5.0, 4.8, and 7.3 min
for the budesonide/formoterol pMDI 320/9-mg, budesonide/
formoterol pMDI 160/9-mg, and formoterol DPI groups,
respectively. Because fewer than 50% of patients achieved
a 15% improvement within the first 60 min after dosing of
study medication in the placebo group, the median time to
15% improvement could not be estimated. Compared withthe day of randomization, the time to achieve a 15%
improvement in FEV1 at the end of treatment (6 months
[study 1]; 12 months [study 2]) generally was maintained
with both budesonide/formoterol pMDI doses but was pro-
longed with formoterol DPI (Fig. 4, Panel B).
Predictors of ATS-defined bronchodilator reversibility
and time to onset of bronchodilation
Formoterol-containing treatment was the most important
predictor of achieving ATS-defined17 reversibility (odds ratio
[OR]: 7.48; 95% confidence interval [CI]: 5.34, 10.48;
p< 0.0001) and a faster time to onset of bronchodilation
(hazard ratio [HR]: 5.02; 95% CI: 3.76, 6.70; p< 0.0001).
Additionally, men and younger patients were significantly
(p< 0.0001) more likely than women and older patients to
achieve ATS-defined reversibility17 (OR: 1.87; 95% CI: 1.41,
2.47andOR: 0.97; 95%CI: 0.95,0.98, respectively) anda faster
time to onset of bronchodilation (HR: 1.59; 95% CI: 1.31, 1.94;
HR: 0.98; 95% CI: 0.97, 0.99, respectively). No significant
associations were observed for other factors assessed
(comorbidities, smoking status, number of pack-years, base-
line symptoms, baseline rescue medication use, or medica-
tionsusedduring run-in [ICS,oxygen,orxanthine]) (p 0.071).Discussion
This manuscript presents a large-scale analysis of broncho-
dilator responsiveness using not only degree of airflow
obstruction change (FEV1) but also lung volume response (IC
and FVC). In addition, the time to onset of bronchodilation in
Figure 3 Mean change from predose to 1-h postdose FEV1 (A), IC (B), and FVC (C) on the day of randomization by study treatment
and COPD severity in both studies (pooled data). BUD, budesonide; DPI, dry powder inhaler; FEV1, forced expiratory volume in 1 s;
FM, formoterol; FVC, forced vital capacity; IC, inspiratory capacity; PBO, placebo; pMDI, pressurized metered-dose inhaler.
Budesonide/formoterol reversibility and onset in COPD 1183
Figure 3 (Continued)
1184 B.R. Celli et al.patients with COPD was analyzed. The proportion of patients
with moderate (stage II) COPD who exhibited FEV1 revers-
ibility was similar after albuterol treatment at screening and
after budesonide/formoterol pMDI treatment on the day of
randomization. The proportion of patients with more severeTable 2 Bronchodilation and estimated time to onset of bronch
within 60 minutes of study drug administration at randomization
BUD/FM
320/9 mg
BUD/FM
160/9 mg
B
F
Predose FEV1 (L), mean (SD)
6-Month study 1.00 (0.41) 1.00 (0.35) 0
12-Month study 1.02 (0.40) 0.97 (0.40) e
15% Improvement in FEV1 randomization
6-Month study
Number (%) of responders 74 (74.7) 71 (69.6) 7
Median time (minutes) 6.8 4.9 6
12-Month study
Number (%) of responders 98 (81.0) 97 (80.2) e
Median time (minutes) 4.2 4.8 e
End of treatment
6-Month study
Number (%) of responders 68 (67.3) 58 (56.9) 6
Median time (minutes) 4.3 6.2 1
12-Month study
Number (%) of responders 88 (72.7) 87 (72.5) e
Median time (minutes) 4.5 4.3 e
BUD, budesonide; FEV1, forced expiratory volume in 1 s; FM, formote
improvement within the first 60 min after dosing; PBO, placebo.COPD (stages III and IV) who showed FEV1 reversibility was
greater with budesonide/formoterol pMDI or formoterol
treatment than with albuterol alone. Improvements in lung
volumes (IC and FVC) also were observed with budesonide/
formoterol pMDI and formoterol, and these improvements inodilation based on a 15% improvement in FEV1 from baseline
and end of treatment.
UD 320 mgþ
M 9 mg
BUD 320 mg FM 9 mg PBO
.98 (0.36) 1.01 (0.39) 1.06 (0.40) 1.08 (0.35)
e 1.00 (0.38) 1.02 (0.43)
4 (69.2) 29 (30.2) 72 (69.2) 28 (25.9)
.2 NA 9.0 NA
e 90 (72.6) 31 (24.8)
e 6.0 NA
6 (61.7) 33 (34.4) 56 (53.8) 32 (29.6)
0.8 NA 18.6 NA
e 74 (59.7) 32 (25.6)
e 16.3 NA
rol; NA, not available because <50% of patients achieved a 15%
Figure 4 KaplaneMeier probability curves for the estimated time to 15% improvement in FEV1 during the first 60 min after
administration of study medication on the day of randomization (A) and end of treatment (B) in the 6-month and 12-month trials.
aStatistical comparison performed for BUD pMDI 320 mgþ FMDPI 9 mg vs BUD/FM pMDI 320/9 mg only; bstatistical comparison for FMDPI
9 mg vs BUD pMDI 320 mg not performed; cp< 0.001 vs PBO; dp< 0.001 vs BUD pMDI; ep< 0.05 vs FM DPI. BUD, budesonide; DPI, dry
powder inhaler; FEV1, forced expiratory volume in 1 second; FM, formoterol; PBO, placebo; pMDI, pressurized metered-dose inhaler.
Budesonide/formoterol reversibility and onset in COPD 1185lung volumes, in contrast to those in FEV1, were comparable
across the spectrum of disease severity. The onset of
bronchodilation is rapid (within 5 min) after budesonide/
formoterol pMDI treatment and this effect is sustained
through 6 and 12 months of treatment.
Currently, there is no consensus regarding a preferred
method of evaluating bronchodilator responsiveness in
patients with COPD. It has been suggested that including
a measure of absolute improvement from baseline in FEV1
may provide an assessment with some degree of indepen-
dence from the baseline value.18 As such, an improvement of
12% þ200 mL in FEV1 and/or FVC is recommended by the
ATS guidelines for assessing bronchodilator responsiveness.19
However, the use of this combined threshold has limitations.
Notably, an improvement in FEV1 of 100e140 mL is consid-
ered clinically meaningful in patients with COPD.20 Thus,
patients with severe or very severe COPD, who tend to have
lower baseline FEV1 values,
20 may not meet the combined
12%þ200 mL criteria, but they could still have a clini-
cally meaningful improvement. In addition, the minimal
important differences for FVC and IC have not been deter-
mined.However, because the combined12%þ200 mLATS
threshold is commonly accepted for assessing and defining
bronchodilator responsiveness in clinical trials,4,6,21,22 its use
is valuable for cross-comparison of results.Using the combined improvement threshold, a substan-
tial percentage of patients in the present analysis
demonstrated FEV1 reversibility within 30 min to budeso-
nide/formoterol pMDI (52e54%) on the day of randomiza-
tion. These results are consistent with those reported by
Tashkin et al., who observed that 54% of patients with
COPD demonstrated FEV1 reversibility after bronchodilator
(80 mg ipratropium and 400 mg albuterol) administration.6
The magnitude of improvement in FEV1 after formoterol-
containing treatment (180e230 mL) also was similar to
that reported by Tashkin et al. after bronchodilator
treatment (229 mL).6
The present study also assessed whether patients who
were initially classified as reversible using the combined
improvement threshold remained so at the end of treatment.
Findings from a previous study showed substantial intra-indi-
vidual variation in reversibility status over time after treat-
ment with ipratropium bromide and albuterol in patients with
moderate to severe COPD.23 In contrast, the present results
showed thatmost patients remained reversible to formoterol-
containing treatment, with a greater proportion of patients
treated with budesonide/formoterol pMDI 320/9 mg main-
taining reversibility versus those treated with the lower dose
of combination therapy or formoterol alone. This effect may
be related to the potentially protective effect of budesonide
1186 B.R. Celli et al.against b2-adrenergic tachyphylaxis; however, these studies
were not designed to assess tachyphylaxis. Corticosteroids
have been shown to increase transcription of the b2-receptor
gene; however, studies suggesting that corticosteroids
protect against b2-adrenergic tachyphylaxis have been
inconsistent.24,25
Notably, in the present analysis, the proportion of
patients demonstrating reversibility within 30 min to budes-
onide/formoterol pMDI (52e54%) at randomization was
different from the proportion of patients who demon-
strated reversibility to albuterol (34e39%) at screening
using the same combined threshold. The reason for this
difference is not clear but could be due, in part, to possible
differences in adherence to the instructions for withholding
previously prescribed bronchodilator therapy at the
screening visit versus the randomization visit or to differ-
ences in the timing of spirometry after albuterol adminis-
tration at screening (15e30 min) compared with sequential
serial assessments up to the 30-min time point after study
medication administration on the day of randomization.
This observation also could be related to differences in
beta agonist activity between albuterol and formoterol,
with albuterol acting as a partial agonist and formoterol as
a full agonist. We acknowledge that comparisons of bron-
chodilator effects on different days and time points may
not provide absolute accuracy. However, the results
suggest that a patient’s response to budesonide/formoterol
pMDI treatment may not be inferred from the results of
standard albuterol testing.
Consistent with the findings reported by Tashkin et al.,
the percentage of patients with COPD who demonstrated
an FEV1 bronchodilator response decreased as the severity
of COPD increased.6 However, in the present analysis,
a larger percentage of patients with very severe COPD
still demonstrated reversibility within 30 min to
formoterol-containing treatments (31e41%) compared with
approximately 20% of very severe COPD patients showing
reversibility to ipratropium and albuterol in the analysis by
Tashkin et al.6 This difference between the 2 analyses may
be related to differences in baseline patient characteristics
or methodologies used. Of interest, in the present analysis
and the analysis by Tashkin et al.,6 the odds of achieving
a bronchodilator response based on ATS criteria was greater
for men than for women and for younger patients compared
with older patients. In the present analysis, the very severe
COPD group also had the highest percentage of men (68%)
compared with the moderate (48%) and severe (65%) COPD
groups.
Lung volume responsiveness in patients with COPD may
be demonstrated using measures of IC1,26 and FVC,27 and
some patients with COPD may show changes in lung volume
after bronchodilator administration without meeting one or
more thresholds for reversibility based on FEV1.
6 In addi-
tion, these measures provide clinically relevant information
since improvements in IC have been correlated with an
increase in exercise endurance and tolerance28 and
a decrease in exertional dyspnea,29,30 and both FVC1 and
the IC/(total lung capacity) ratio31 have been shown to be
predictors of all-cause mortality in patients with COPD. In
the present analysis, a substantial percentage of patients
receiving budesonide/formoterol pMDI or formoterol
treatments demonstrated lung volume response based on ICand FVC improvement with no clear pattern of response
observed across COPD severity categories. The magnitude
of improvement in postdose FVC from baseline on the day
of randomization was lower in the present studies
(350e410 mL) compared with the study by Tashkin et al.
(471 mL).6 This difference may be due to the maximal
bronchodilation in the Tashkin et al. study, where patients
received 4 inhalations of ipratropium (80 mg) followed
60 min later by 4 inhalations of albuterol (400 mg) before
postbronchodilator spirometry.6 In contrast, patients in the
present studies who were randomized to a budesonide/
formoterol pMDI or formoterol treatment received 9 mg of
formoterol before postbronchodilator spirometry.
In the present analysis, a greater proportion of patients
with moderate COPD demonstrated bronchodilator respon-
siveness based on improvements in FEV1, IC, and FVC with
budesonide/formoterol pMDI compared with formoterol.
Although it is not clear what role budesonide may play with
regard to acute effects on pulmonary function, these
results generally are consistent with the results of a post
hoc analysis of efficacy data from the TOwards a Revolution
in COPD Health (TORCH) study, in which a numerical
decrease in the annual rate of exacerbations was observed
with salmeterol/fluticasone versus salmeterol alone at
early stages of the disease (GOLD stage II [0.57 vs 0.71,
respectively]; GOLD stage III [0.91 vs 1.08, respectively]),
but not at GOLD stage IV (1.54 vs 1.40, respectively).11
Taken together, these results suggest that the addition of
ICS to LABA therapy may result in clinical benefit at milder
stages of the disease.
The time to onset of bronchodilation of budesonide/
formoterol pMDI has not been explored previously in
patients with COPD. In the current study, the time to onset
was rapid (within 5 min) with both budesonide/formoterol
pMDI doses and formoterol on the day of randomization. At
the end of treatment, the time to onset of bronchodilation
was maintained with the budesonide/formoterol treat-
ments but was prolonged with formoterol treatment.
Possible explanations for these results may be that the
budesonide component of the budesonide/formoterol pMDI
product protects against a decrease in responsiveness to
formoterol over time or that there is a synergistic effect
between the budesonide and formoterol components;
however, further studies are needed to investigate these or
other possible mechanisms. Rapid onset of bronchodilation
may offer clinical benefits in symptom control. The results
of a recent survey of 803 patients with COPD indicate that
COPD symptoms are particularly severe in the morning.32
A medication providing rapid relief could be of particular
importance to patients with COPD.
In summary, the present findings suggest that a large
percentage of patients with moderate to very severe COPD
experience the ATS-defined threshold for reversibility after
treatment with formoterol, administered alone or in
combination with budesonide. The improvements in IC and
FVC on the day of randomization provide evidence of rapid
improvements in lung volumes with budesonide/formoterol
pMDI therapy in patients with COPD. Budesonide/for-
moterol pMDI also demonstrated a rapid (within 5 min)
onset of bronchodilation based on FEV1 that was main-
tained through 6 or 12 months of treatment, which may
have clinical relevance to symptomatic patients with COPD.
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